Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -5.37%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
Evolus demonstrated strong financial performance with significant revenue growth and profitability achieved ahead of schedule, along with successful product approvals and market expansion. However, there are concerns regarding market conditions and managing cash flow in Q1 2025.Company Guidance
In the recent earnings call for Evolus, the company reported achieving profitability in the fourth quarter of 2024, surpassing their target by one year. Notably, Evolus experienced over 30% revenue growth for the fifth consecutive year, with the U.S. market share nearing 14%. The company ended 2024 with global net revenues of $266.3 million, marking a 32% increase over 2023, and set a 2025 revenue guidance of $345 to $355 million. Evolus also expanded its customer base by adding over 2,900 new accounts, totaling more than 15,000 purchasing accounts. The launch of Evolys, approved by the FDA, is expected to increase the U.S. market by 78%, contributing 8% to 10% of total revenue in 2025. Evolus aims for $700 million in revenue by 2028, supported by strong international growth, particularly in the UK, Australia, and Spain, with a target of $100 million in international revenue by 2028. The company emphasized its focus on digital strategy and consumer engagement, with Evolys Rewards surpassing 1.1 million users, a 40% increase from the previous year.Achieving Profitability
Evolus achieved meaningful profitability in Q4 2024 and delivered profitability for the full year, one year ahead of their stated goal.
Revenue Growth
Revenue growth exceeded 30% for the fifth consecutive year, with 2024 total net revenues of $266.3 million, representing a 32% increase over 2023.
Expansion of Product Portfolio
FDA approval of Evolys Form and Evolys Smooth injectable gels, expanding the total addressable market in the US by 78%.
Increase in Market Share
US market share approaching 14%, with over 2,900 new accounts added in 2024.
International Growth
Expanded direct presence in Australia and Spain, with the goal of $100 million in international revenue by 2028.
Strong Cash Position
Ended Q4 2024 with $87 million in cash, reflecting strong sales growth and efficient cash collection.
---
EOLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EOLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $14.35 | $14.17 | -1.25% |
| Nov 06, 2024 | $16.81 | $14.29 | -14.99% |
| Jul 31, 2024 | $12.42 | $14.04 | +13.04% |
| May 07, 2024 | $13.42 | $13.26 | -1.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evolus Inc (EOLS) report earnings?
Evolus Inc (EOLS) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Evolus Inc (EOLS) earnings time?
Evolus Inc (EOLS) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EOLS EPS forecast?
EOLS EPS forecast for the fiscal quarter 2025 (Q1) is -0.09.
---